Search

Your search keyword '"Stefani, Piero Maria"' showing total 37 results
Start Over Author "Stefani, Piero Maria"
37 results on '"Stefani, Piero Maria"'

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

2. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Author

Malinverni, Chiara, Bernardelli, Andrea, Glimelius, Ingrid, Mirandola, Massimo, Smedby, Karin E., Tisi, Maria Chiara, Giné, Eva, Albertsson-Lindblad, Alexandra, Marin-Niebla, Ana, Di Rocco, Alice, Moita, Filipa, Sciarra, Roberta, Bašić-Kinda, Sandra, Hess, Georg, Ohler, Anke, Eskelund, Christian W., Re, Alessandro, Ferrarini, Isacco, Kolstad, Arne, Räty, Riikka, Quaglia, Francesca Maria, Eyre, Toby A., Scapinello, Greta, Stefani, Piero Maria, Morello, Lucia, Nassi, Luca, Hohaus, Stefan, Ragaini, Simone, Zilioli, Vittorio Ruggero, Bruna, Riccardo, Cocito, Federica, Arcari, Annalisa, Jerkeman, Mats, and Visco, Carlo

Published
2024
Full Text
View/download PDF

3. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Author

Ferrero, Simone, Grimaldi, Daniele, Genuardi, Elisa, Drandi, Daniela, Zaccaria, Gian Maria, Alessandria, Beatrice, Ghislieri, Marco, Ferrante, Martina, Evangelista, Andrea, Mantoan, Barbara, De Luca, Gabriele, Stefani, Piero Maria, Benedetti, Fabio, Casaroli, Ivana, Zanni, Manuela, Castellino, Claudia, Pavone, Vincenzo, Petrini, Mario, Re, Francesca, Hohaus, Stefan, Musuraca, Gerardo, Cascavilla, Nicola, Ghiggi, Chiara, Liberati, Anna Marina, Cortelazzo, Sergio, and Ladetto, Marco

Published
2022
Full Text
View/download PDF

4. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Author

Visco, Carlo, Di Rocco, Alice, Evangelista, Andrea, Quaglia, Francesca Maria, Tisi, Maria Chiara, Morello, Lucia, Zilioli, Vittorio Ruggero, Rusconi, Chiara, Hohaus, Stefan, Sciarra, Roberta, Re, Alessandro, Tecchio, Cristina, Chiappella, Annalisa, Marin-Niebla, Ana, McCulloch, Rory, Gini, Guido, Perrone, Tommasina, Nassi, Luca, Pennese, Elsa, Stefani, Piero Maria, Cox, Maria Christina, Bozzoli, Valentina, Fabbri, Alberto, Polli, Valentina, Ferrero, Simone, Celis, Maria Isabel Alvarez De, Sica, Antonello, Petrucci, Luca, Arcaini, Luca, Rule, Simon, Krampera, Mauro, Vitolo, Umberto, and Balzarotti, Monica

Published
2021
Full Text
View/download PDF

5. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, Luminari, Stefano, Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97

Published
2024

6. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

Author

Olivieri, Jacopo, Mosna, Federico, Pelosini, Matteo, Fama, Angelo, Rattotti, Sara, Giannoccaro, Margherita, Carli, Giuseppe, Tisi, Maria Chiara, Ferrero, Simone, Sgherza, Nicola, Mazzone, Anna Maria, Marino, Dario, Calimeri, Teresa, Loseto, Giacomo, Saraceni, Francesco, Tomei, Gabriella, Sica, Simona, Perali, Giulia, Codeluppi, Katia, Billio, Atto, Olivieri, Attilio, Orciuolo, Enrico, Matera, Rossella, Stefani, Piero Maria, Borghero, Carlo, Ghione, Paola, Cascavilla, Nicola, Lanza, Francesco, Chiusolo, Patrizia, Finotto, Silvia, Federici, Irene, Gherlinzoni, Filippo, Centurioni, Riccardo, Fanin, Renato, and Zaja, Francesco

Published
2018
Full Text
View/download PDF

7. S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

Author

Ladetto, Marco, primary, Tavarozzi, Rita, additional, Evangelista, Andrea, additional, Genuardi, Elisa, additional, Drandi, Daniela, additional, Mian, Michael, additional, Zanni, Manuela, additional, Cavallo, Federica, additional, Rocco, Alice DI, additional, Stefoni, Vittorio, additional, Pagani, Chiara, additional, Re, Alessandro, additional, Chiappella, Annalisa, additional, Balzarotti, Monica, additional, Zilioli, Vittorio Ruggero, additional, Da Silva, Maria Gomes, additional, Arcaini, Luca, additional, Molinari, Annalia, additional, Ballerini, Filippo, additional, Ferreri, Andrés José María, additional, Benedetti, Fabio, additional, Stefani, Piero Maria, additional, Puccini, Benedetta, additional, Stelitano, Caterina, additional, Bossi, Elisa, additional, Luppi, Mario, additional, Ciccone, Giovannino, additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Ferrero, Simone, additional, and Cortelazzo, Sergio, additional

Published
2023
Full Text
View/download PDF

8. Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Author

Visco, Carlo, Di Rocco, Alice, Evangelista, Andrea, Quaglia, Francesca Maria, Tisi, Maria Chiara, Morello, Lucia, Zilioli, Vittorio Ruggero, Rusconi, Chiara, Hohaus, Stefan, Sciarra, Roberta, Re, Alessandro, Tecchio, Cristina, Chiappella, Annalisa, Marin-Niebla, Ana, McCulloch, Rory, Gini, Guido, Perrone, Tommasina, Nassi, Luca, Pennese, Elsa, Stefani, Piero Maria, Cox, Maria Christina, Bozzoli, Valentina, Fabbri, Alberto, Polli, Valentina, Ferrero, Simone, De Celis, Maria Isabel Alvarez, Sica, Antonello, Petrucci, Luca, Arcaini, Luca, Rule, Simon, Krampera, Mauro, Vitolo, Umberto, and Balzarotti, Monica

Published
2021
Full Text
View/download PDF

9. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Author

Pinto, Antonio, primary, Guardalben, Emanuele, additional, Caltagirone, Marco, additional, Piparo, Chiara, additional, Patti, Caterina, additional, Pennese, Elsa, additional, De Lorenzo, Sonya, additional, Pavone, Vincenzo, additional, Consoli, Ugo, additional, Piazza, Francesco, additional, Capponi, Monia, additional, Puccini, Benedetta, additional, Baldini, Luca, additional, Pulsoni, Alessandro, additional, Hohaus, Stefan, additional, Stefani, Piero Maria, additional, Santini, Simone, additional, Zilioli, Vittorio Ruggero, additional, Stelitano, Caterina, additional, Arcaini, Luca, additional, Gritti, Giuseppe, additional, Ladetto, Marco, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

10. IDH2 R172mutation in angioimmunoblastic T‐cell lymphoma: A retrospective multicenter case series

Author

Riva, Marcello, primary, Tisi, Maria Chiara, additional, Bertorelle, Roberta, additional, Famengo, Barbara, additional, D'Amore, Emanuele Stefano Giovanni, additional, Pizzi, Marco, additional, Parisi, Alice, additional, Boscato, Elena, additional, Mazzucco, Maddalena, additional, Semenzato, Gianpietro, additional, Krampera, Mauro, additional, Gherlinzoni, Filippo, additional, Trentin, Livio, additional, Ruggeri, Marco, additional, Visco, Carlo, additional, Stefani, Piero Maria, additional, and Piazza, Francesco, additional

Published
2022
Full Text
View/download PDF

12. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma

Author

Ferrero, Simone, Grimaldi, Daniele, Genuardi, Elisa, Drandi, Daniela, Zaccaria, Gian Maria, Alessandria, Beatrice, Ghislieri, Marco, Ferrante, Martina, Evangelista, Andrea, Mantoan, Barbara, De Luca, Gabriele, Stefani, Piero Maria, Benedetti, Fabio, Casaroli, Ivana Rita, Zanni, Manuela, Castellino, Claudia, Pavone, Vincenzo, Petrini, Mario, Francesca, Re, Hohaus, Stefan, Musuraca, Gerardo, Cascavilla, Nicola, Ghiggi, Chiara, Liberati, Anna Marina Marina, Cortelazzo, Sergio, and Ladetto, Marco

Subjects
Lymphoid Neoplasia
Published
2022

13. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

Author

Casadei, Beatrice, primary, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Patti, Caterina, additional, Stefani, Piero Maria, additional, Cuneo, Antonio, additional, Margiotta Casaluci, Gloria, additional, Visco, Carlo, additional, Gini, Guido, additional, Pane, Fabrizio, additional, D’Alò, Francesco, additional, Luzi, Debora, additional, Cantonetti, Maria, additional, Pozzi, Samantha, additional, Musuraca, Gerardo, additional, Rosignoli, Chiara, additional, Arcari, Annalisa, additional, Kovalchuk, Sofya, additional, Tani, Monica, additional, Tisi, Maria Chiara, additional, Petrini, Mario, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

14. IDH2R172 mutation in angioimmunoblastic T‐cell lymphoma: A retrospective multicenter case series.

Author

Riva, Marcello, Tisi, Maria Chiara, Bertorelle, Roberta, Famengo, Barbara, D'Amore, Emanuele Stefano Giovanni, Pizzi, Marco, Parisi, Alice, Boscato, Elena, Mazzucco, Maddalena, Semenzato, Gianpietro, Krampera, Mauro, Gherlinzoni, Filippo, Trentin, Livio, Ruggeri, Marco, Visco, Carlo, Stefani, Piero Maria, and Piazza, Francesco

Subjects
T-cell lymphoma, FOLLICULAR dendritic cells, DIFFUSE large B-cell lymphomas
Abstract

Thirty-one patients (75%) received anthracycline/etoposide-based therapy (9 out of 31 were I IDH2 i SP I R172 i sp mutated) and 4 of them (4/31, 13%) were consolidated with autologous stem-cell transplantation (ASCT) in first complete remission (CR1); ASCT recipients were all I IDH2 i SP I WT i sp . Patients with I IDH2 i SP I WT i sp AITL achieved CR1 in 14/32 (44%), as opposed to 9/10 (90%) of I IDH2 i SP I R172 i sp patients ( I p i = .018). Thirty-two patients (32/42, 76%) were I IDH2 i SP I WT i sp , and 10 patients (10/42, 24%) were I IDH2 i SP I R172 i sp mutated. [Extracted from the article]

Published
2023
Full Text
View/download PDF

15. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience

Author

Massaro, Fulvio, primary, Pavone, Vincenzo, additional, Stefani, Piero Maria, additional, Botto, Barbara, additional, Pulsoni, Alessandro, additional, Patti, Caterina, additional, Cantonetti, Maria, additional, Visentin, Andrea, additional, Scalzulli, Potito Rosario, additional, Rossi, Andrea, additional, Galimberti, Sara, additional, Cimminiello, Michele, additional, Gini, Guido, additional, Musso, Maurizio, additional, Sorio, Marco, additional, Arcari, Annalisa, additional, Zilioli, Vittorio Ruggero, additional, Luppi, Mario, additional, Mannina, Donato, additional, Fabbri, Alberto, additional, Pietrantuono, Giuseppe, additional, Annibali, Ombretta, additional, Tafuri, Agostino, additional, Prete, Eleonora, additional, Mulè, Antonino, additional, Barbolini, Elisa, additional, Marcheselli, Luigi, additional, Luminari, Stefano, additional, and Merli, Francesco, additional

Published
2021
Full Text
View/download PDF

16. Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Author

Visco, Carlo, Tabanelli, Valentina, Sacchi, Maria Vittoria, Evangelista, Andrea, Ferrarini, Isacco, Tisi, Maria Chiara, Merli, Anna, Fiori, Stefano, Zilioli, Vittorio Ruggero, Re, Alessandro, Castellino, Claudia, Piazza, Francesco, Corradini, Paolo, Hohaus, Stefan, Musuraca, Gerardo, Rossi, Francesca Gaia, Puccini, Benedetta, Cavallo, Federica, Ballerini, Filippo, Sciarra, Roberta, Di Rocco, Alice, Arcari, Annalisa, Boccomini, Carola, Merli, Francesco, Gini, Guido, Tani, Monica, Bruna, Riccardo, Pavone, Vincenzo, Ferreri, Andrés José María, Santoro, Armando, Patti, Caterina, Loseto, Giacomo, Ladetto, Marco, Merli, Michele, Spina, Michele, Zinzani, Pier Luigi, Stefani, Piero Maria, Usai, Sara, Pileri, Stefano, and Balzarotti, Monica

Published
2023
Full Text
View/download PDF

17. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia

Author

Todeschini, Giuseppe, Bonifacio, Massimiliano, Tecchio, Cristina, Balter, Rita, Carli, Giuseppe, Stefani, Piero Maria, Adami, Fausto, Zamò, Alberto, Tos, Angelo Paolo Dei, Marino, Filippo, Gherlinzoni, Filippo, Marradi, Pierluigi, Semenzato, Giampietro, and Pizzolo, Giovanni

Published
2012
Full Text
View/download PDF

18. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Author

Visco, Carlo, primary, Di Rocco, Alice, additional, Evangelista, Andrea, additional, Quaglia, Francesca Maria, additional, Tisi, Maria Chiara, additional, Morello, Lucia, additional, Zilioli, Vittorio Ruggero, additional, Rusconi, Chiara, additional, Hohaus, Stefan, additional, Sciarra, Roberta, additional, Re, Alessandro, additional, Tecchio, Cristina, additional, Chiappella, Annalisa, additional, Marin-Niebla, Ana, additional, McCulloch, Rory, additional, Gini, Guido, additional, Perrone, Tommasina, additional, Nassi, Luca, additional, Pennese, Elsa, additional, Stefani, Piero Maria, additional, Cox, Maria Christina, additional, Bozzoli, Valentina, additional, Fabbri, Alberto, additional, Polli, Valentina, additional, Ferrero, Simone, additional, Celis, Maria Isabel Alvarez De, additional, Sica, Antonello, additional, Petrucci, Luca, additional, Arcaini, Luca, additional, Rule, Simon, additional, Krampera, Mauro, additional, Vitolo, Umberto, additional, and Balzarotti, Monica, additional

Published
2020
Full Text
View/download PDF

19. MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ischemia

Author

Spinetti, Gaia, primary, Sangalli, Elena, primary, Tagliabue, Elena, primary, Maselli, Davide, primary, Colpani, Ornella, primary, Ferland-McCollough, David, primary, Carnelli, Franco, primary, Orlando, Patrizia, primary, Paccagnella, Agostino, primary, Furlan, Anna, primary, Stefani, Piero Maria, primary, Sambado, Luisa, primary, Sambataro, Maria, primary, and Madeddu, Paolo, primary

Published
2020
Full Text
View/download PDF

22. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience.

Author

Massaro, Fulvio, Pavone, Vincenzo, Stefani, Piero Maria, Botto, Barbara, Pulsoni, Alessandro, Patti, Caterina, Cantonetti, Maria, Visentin, Andrea, Scalzulli, Potito Rosario, Rossi, Andrea, Galimberti, Sara, Cimminiello, Michele, Gini, Guido, Musso, Maurizio, Sorio, Marco, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Luppi, Mario, Mannina, Donato, and Fabbri, Alberto

Subjects
STEM cell transplantation, HODGKIN'S disease, DISEASE relapse, PROGRESSION-free survival, SALVAGE therapy
Abstract

The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression‐free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post‐ASCT BV maintenance in the real‐life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow‐up was 20 months. Patients presented a median of two lines of treatment pre‐ASCT, with 51% receiving BV. Twenty‐nine percent of patients had at least two high‐risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET‐CT, a Deauville score (DS) of 1–3 was reported in 75% and 78% of pre‐ and post‐ASCT evaluations, respectively. Grade 3–4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three‐year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3‐year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post‐ASCT DS 4–5 (HR 3.14; p = 0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post‐ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, Giuseppe, Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Milone, G., Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, Placanica, Paola, Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, for the Gruppo Italiano Trapianto di Midollo Osseo, (GITMO), Associazione Microbiologi Clinici Italiani, (AMCLI), Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, G., Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, and Placanica, Paola

Subjects
0301 basic medicine, Male, Transplantation Conditioning, Drug Resistance, Bacteremia, 0302 clinical medicine, epidemiology, Gram negative bacteremia, multidrug resistance, stem cell transplant, survival, Risk Factors, Drug Resistance, Multiple, Bacterial, Epidemiology, Medicine, Age Factor, Prospective Studies, Prospective cohort study, Child, Transplantation, Homologou, education.field_of_study, Incidence (epidemiology), Incidence, Bacterial, Age Factors, Hematopoietic Stem Cell Transplantation, Middle Aged, Transplantation, Autologou, surgical procedures, operative, Infectious Diseases, Italy, Child, Preschool, Female, medicine.symptom, Multiple, Autologous, Human, Homologous, Microbiology (medical), Adult, medicine.medical_specialty, Adolescent, 030106 microbiology, Population, Transplantation, Autologous, 03 medical and health sciences, Young Adult, Internal medicine, Gram-Negative Bacteria, Gram-Negative Bacterial Infection, Escherichia coli, Humans, Transplantation, Homologous, Preschool, education, Aged, Gram-Negative Bacterial Infections, Infant, Transplantation, business.industry, Risk Factor, medicine.disease, Prospective Studie, Carriage, Otitis, business, Settore MED/15 - Malattie del Sangue, 030215 immunology
Abstract

Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45–3.13; P Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.

Published
2017

24. MYC Rearranged Aggressive B-Cell Lymphomas

Author

Tisi, Maria Chiara, Ferrero, Simone, Dogliotti, Irene, Tecchio, Cristina, Carli, Giuseppe, Novo, Mattia, Stefani, Piero Maria, Rattotti, Sara, Balzarotti, Monica, Marino, Dario, Pelosini, Matteo, Romano, Alessandra, Flenghi, Leonardo, Zilioli, Vittorio Ruggero, Calimeri, Teresa, Di Napoli, Arianna, Zanni, Manuela, Finolezzi, Erica, Mosna, Federico, Gini, Guido, Mansueto, Giovanna, Di Rocco, Alice, Tomei, Gabriella, Sgherza, Nicola, Olivieri, Jacopo, Nassi, Luca, Piazza, Francesco, Fama, Angelo, Greco, Antonio, Giannoccaro, Margherita, Mazzone, Anna Maria, Visco, Carlo, Loseto, Giacomo, and Zaja, Francesco

Subjects
aggressive B lymphoma, C-myc rearrangement, C-myc rearrangement, aggressive B lymphoma
Published
2019

26. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)

Author

Tisi, Maria Chiara, primary, Ferrero, Simone, additional, Dogliotti, Irene, additional, Tecchio, Cristina, additional, Carli, Giuseppe, additional, Novo, Mattia, additional, Stefani, Piero Maria, additional, Rattotti, Sara, additional, Balzarotti, Monica, additional, Marino, Dario, additional, Pelosini, Matteo, additional, Romano, Alessandra, additional, Flenghi, Leonardo, additional, Zilioli, Vittorio Ruggero, additional, Calimeri, Teresa, additional, Di Napoli, Arianna, additional, Zanni, Manuela, additional, Finolezzi, Erica, additional, Mosna, Federico, additional, Gini, Guido, additional, Mansueto, Giovanna, additional, Di Rocco, Alice, additional, Tomei, Gabriella, additional, Sgherza, Nicola, additional, Olivieri, Jacopo, additional, Nassi, Luca, additional, Piazza, Francesco, additional, Fama, Angelo, additional, Greco, Antonio, additional, Giannoccaro, Margherita, additional, Mazzone, Anna Maria, additional, Visco, Carlo, additional, Loseto, Giacomo, additional, and Zaja, Francesco, additional

Published
2019
Full Text
View/download PDF

27. 621-P: Cardiovascular Mortality and Orthostatic Hypotension in Type 2 Diabetic Patients (T2D) with Lower Limb Lesions—Italian Diabetic Patients' Association-Section of Treviso Project

Author

SAMBATARO, MARIA, primary, SAMBADO, LUISA, additional, SPINETTI, GAIA, additional, SEGANFREDDO, ELENA, additional, TREVISIOL, ENRICA, additional, MARCON, MARIALISA, additional, STEFANI, PIERO MARIA, additional, FURLAN, ANNA, additional, CACCIATORE, MATILDE, additional, and PACCAGNELLA, AGOSTINO, additional

Published
2019
Full Text
View/download PDF

28. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)

Author

Michele Spina, Pier Luigi Zinzani, Francesco Merli, Stefani Piero Maria, Andrea Gallamini, Vittorio Stefoni, Alberto Biggi, Alessandro Levis, Sancetta Rosaria, Luigi Rigacci, Umberto Vitolo, Benedetta Puccini, Alberto Bosi, Antonio Castagnoli, Manuel Gotti, Monica Balzarotti, Caterina Stelitano, L. Rigacci, B. Puccini, P. L. Zinzani, A. Biggi, A. Castagnoli, F. Merli, M. Balzarotti, C. Stelitano, M. Spina, U. Vitolo, V. Stefoni, A. Levi, M. Gotti, S. Rosaria, S. P. Maria, A. Bosi, and A. Gallamini

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, HL, Disease-Free Survival, Predictive Value of Tests, Internal medicine, Humans, Medicine, Stage (cooking), Survival rate, Aged, Neoplasm Staging, Univariate analysis, medicine.diagnostic_test, business.industry, ABVD, Retrospective cohort study, Hematology, Middle Aged, Hodgkin Disease, Radiography, Survival Rate, Radiation therapy, Positron emission tomography, Positron-Emission Tomography, Predictive value of tests, Female, business, Nuclear medicine, Follow-Up Studies, medicine.drug
Abstract

This retrospective study included 246 patients with a new diagnosis of Hodgkin Lymphoma (HL) with a localized-stage (IA-IIA), consecutively admitted from January 2002 to December 2008, by twelve Italian hematological centers on behalf of Fondazione Italiana Linfomi (FIL). Patients were staged at baseline and after two cycles of chemotherapy with PET. All patients were treated with four cycles of ABVD followed by involved-field radiotherapy. No treatment change, based on PET-2 results was allowed. Endpoint of the study was the predictive role of PET-2 on 2-y failure-free survival (FFS). PET-2 was positive in 36 patients (15%) and negative in 210. After a mean follow-up of 46 (3–105) months 19/36 PET-2 positive patients progressed or relapsed and 17 achieved and maintained a CCR. The positive and negative predictive value of a PET2 was 53% and 95%, respectively. The sensibility, specificity and accuracy of PET2 were 65.5%, 92% and 89%, respectively. PET-2 positive scans were centrally reviewed according to the recently defined Deauville Criteria. Upon review the PPV and NPV was 73% and 96% overall. Factors with prognostic significance for progression in univariate analysis were a positive PET-2 (P = 0.000) and the presence of bulky disease (P

Published
2015
Full Text
View/download PDF

30. MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia.

Author

Spinetti, Gaia, Sangalli, Elena, Tagliabue, Elena, Maselli, Davide, Colpani, Ornella, Ferland-McCollough, David, Carnelli, Franco, Orlando, Patrizia, Paccagnella, Agostino, Furlan, Anna, Stefani, Piero Maria, Sambado, Luisa, Sambataro, Maria, and Madeddu, Paolo

Subjects
VASCULAR endothelial cells, BONE marrow cells, CELL migration, ENDOTHELIAL cells, TYPE 2 diabetes
Abstract

OBJECTIVE: In patients with type 2 diabetes (T2D) and critical limb ischemia (CLI), migration of circulating CD34+ cells predicted cardiovascular mortality at 18 months after revascularization. This study aimed to provide long-term validation and mechanistic understanding of the biomarker. RESEARCH DESIGN AND METHODS: The association between CD34+ cell migration and cardiovascular mortality was reassessed at 6 years after revascularization. In a new series of T2D-CLI and control subjects, immuno-sorted bone marrow CD34+ cells were profiled for miRNA expression and assessed for apoptosis and angiogenesis activity. The differentially regulated miRNA-21 and its proapoptotic target, PDCD4, were titrated to verify their contribution in transferring damaging signals from CD34+ cells to endothelial cells. RESULTS: Multivariable regression analysis confirmed that CD34+ cell migration forecasts long-term cardiovascular mortality. CD34+ cells from T2D-CLI patients were more apoptotic and less proangiogenic than those from control subjects and featured miRNA-21 downregulation, modulation of several long noncoding RNAs acting as miRNA-21 sponges, and upregulation of the miRNA-21 proapoptotic target PDCD4. Silencing miR-21 in control CD34+ cells phenocopied the T2D-CLI cell behavior. In coculture, T2D-CLI CD34+ cells imprinted naive endothelial cells, increasing apoptosis, reducing network formation, and modulating the TUG1 sponge/miRNA-21/PDCD4 axis. Silencing PDCD4 or scavenging reactive oxygen species protected endothelial cells from the negative influence of T2D-CLI CD34+ cells. CONCLUSIONS: Migration of CD34+ cells predicts long-term cardiovascular mortality in T2D-CLI patients. An altered paracrine signaling conveys antiangiogenic and proapoptotic features from CD34+ cells to the endothelium. This damaging interaction may increase the risk for life-threatening complications. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. Proinsulin‐expressing dendritic cells in type 2 neuropathic diabetic patients with and without foot lesions

Author

Sambataro, Maria, primary, Sambado, Luisa, additional, Trevisiol, Enrica, additional, Cacciatore, Matilde, additional, Furlan, Anna, additional, Stefani, Piero Maria, additional, Seganfreddo, Elena, additional, Durante, Elisabetta, additional, Conte, Stefania, additional, Bella, Silvia Della, additional, Paccagnella, Agostino, additional, and Tos, Angelo Paolo, additional

Published
2018
Full Text
View/download PDF

32. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia

Author

Todeschini, Giuseppe, primary, Bonifacio, Massimiliano, additional, Tecchio, Cristina, additional, Balter, Rita, additional, Carli, Giuseppe, additional, Stefani, Piero Maria, additional, Adami, Fausto, additional, Zamò, Alberto, additional, Tos, Angelo Paolo Dei, additional, Marino, Filippo, additional, Gherlinzoni, Filippo, additional, Marradi, Pierluigi, additional, Semenzato, Giampietro, additional, and Pizzolo, Giovanni, additional

Published
2011
Full Text
View/download PDF

35. Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.

Author

Zamagni, Elena, primary, Testoni, Nicoletta, additional, Terragna, Carolina, additional, Tacchetti, Paola, additional, Nicci, Chiara, additional, Renzulli, Matteo, additional, Tosi, Patrizia, additional, Fiacchini, Mauro, additional, Patriarca, Francesca, additional, Di Raimondo, Francesco, additional, Perrone, Giulia, additional, Catalano, Lucio, additional, Casulli, Francesco, additional, Ceccolini, Michela, additional, Volpe, Silvestro, additional, Masini, Luciano, additional, Ledda, Antonio, additional, Brioli, Annamaria, additional, Falcioni, Sadia, additional, Gozzetti, Alessandro, additional, Califano, Catello, additional, Pallotti, Mariacaterina, additional, Cellini, Claudia, additional, Carubelli, Affra, additional, Stefani, Piero Maria, additional, Pantani, Lucia, additional, Baccarani, Michele, additional, and Cavo, Michele, additional

Published
2007
Full Text
View/download PDF

36. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)

Author

Maria Chiara Tisi, Simone Ferrero, Irene Dogliotti, Cristina Tecchio, Giuseppe Carli, Mattia Novo, Piero Maria Stefani, Sara Rattotti, Monica Balzarotti, Dario Marino, Matteo Pelosini, Alessandra Romano, Leonardo Flenghi, Vittorio Ruggero Zilioli, Teresa Calimeri, Arianna Di Napoli, Manuela Zanni, Erica Finolezzi, Federico Mosna, Guido Gini, Giovanna Mansueto, Alice Di Rocco, Gabriella Tomei, Nicola Sgherza, Jacopo Olivieri, Luca Nassi, Francesco Piazza, Angelo Fama, Antonio Greco, Margherita Giannoccaro, Anna Maria Mazzone, Carlo Visco, Giacomo Loseto, Francesco Zaja, on behalf of the Fondazione Italiana Linfomi Postgraduate Master course, Tisi, Maria Chiara, Ferrero, Simone, Dogliotti, Irene, Tecchio, Cristina, Carli, Giuseppe, Novo, Mattia, Stefani, Piero Maria, Rattotti, Sara, Balzarotti, Monica, Marino, Dario, Pelosini, Matteo, Romano, Alessandra, Flenghi, Leonardo, Zilioli, Vittorio Ruggero, Calimeri, Teresa, Di Napoli, Arianna, Zanni, Manuela, Finolezzi, Erica, Mosna, Federico, Gini, Guido, Mansueto, Giovanna, Di Rocco, Alice, Tomei, Gabriella, Sgherza, Nicola, Olivieri, Jacopo, Nassi, Luca, Piazza, Francesco, Fama, Angelo, Greco, Antonio, Giannoccaro, Margherita, Mazzone, Anna Maria, Visco, Carlo, Loseto, Giacomo, and Zaja, Francesco

Subjects
Letter, business.industry, lcsh:RC633-647.5, MYC, NHL, lymphoma, Hematology, lcsh:Diseases of the blood and blood-forming organs, Text mining, medicine.anatomical_structure, Cancer research, medicine, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, business, B cell
Abstract

Supplemental Digital Content is available in the text.

Published
2019

37. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

Author

Filippo Gherlinzoni, Maria Chiara Tisi, Irene Federici, Giulia Perali, Nicola Cascavilla, Francesco Saraceni, Gabriella Tomei, Anna Maria Mazzone, Federico Mosna, Jacopo Olivieri, Enrico Orciuolo, Simone Ferrero, Piero Maria Stefani, Giuseppe Carli, Paola Ghione, Francesco Lanza, Matteo Pelosini, Margherita Giannoccaro, Silvia Finotto, Renato Fanin, Katia Codeluppi, T. Calimeri, Atto Billio, Patrizia Chiusolo, Carlo Borghero, Giacomo Loseto, Sara Rattotti, Dario Marino, Riccardo Centurioni, R. Matera, Nicola Sgherza, Simona Sica, Attilio Olivieri, Angelo Fama, Francesco Zaja, Olivieri, Jacopo, Mosna, Federico, Pelosini, Matteo, Fama, Angelo, Rattotti, Sara, Giannoccaro, Margherita, Carli, Giuseppe, Tisi, Maria Chiara, Ferrero, Simone, Sgherza, Nicola, Mazzone, Anna Maria, Marino, Dario, Calimeri, Teresa, Loseto, Giacomo, Saraceni, Francesco, Tomei, Gabriella, Sica, Simona, Perali, Giulia, Codeluppi, Katia, Billio, Atto, Olivieri, Attilio, Orciuolo, Enrico, Matera, Rossella, Stefani, Piero Maria, Borghero, Carlo, Ghione, Paola, Cascavilla, Nicola, Lanza, Francesco, Chiusolo, Patrizia, Finotto, Silvia, Federici, Irene, Gherlinzoni, Filippo, Centurioni, Riccardo, Fanin, Renato, and Zaja, Francesco

Subjects
Male, Oncology, medicine.medical_specialty, Transplantation conditioning, Lymphoma, Transplantation, Autologous, BEAM regimen, Fotemustine, medicine.medical_treatment, Hematopoietic stem cell transplantation, Autologou, Transplantation, Autologous, NO, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, immune system diseases, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Hematology, Melphalan, Etoposide, Retrospective Studies, Chemotherapy, Carmustine, business.industry, Cytarabine, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Middle Aged, medicine.disease, Italy, 030220 oncology & carcinogenesis, Female, Transplantation Conditioning, business, 030215 immunology, medicine.drug
Abstract

BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results